SHAREHOLDER SUPPORT AGREEMENTShareholder Support Agreement • December 6th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledDecember 6th, 2018 Company Industry JurisdictionThis SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company limited by shares with company registration number 00 949417 and registered in England and Wales (“Shareholder”), acting as agent for and on behalf of Invesco High Income Fund (“Fund”).
SHAREHOLDER SUPPORT AGREEMENTShareholder Support Agreement • December 6th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledDecember 6th, 2018 Company Industry JurisdictionThis SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company limited by shares with company registration number 00 949417 and registered in England and Wales (“Shareholder”), acting as agent for and on behalf of Invesco Income Fund (“Fund”).
SHAREHOLDER SUPPORT AGREEMENTShareholder Support Agreement • December 6th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledDecember 6th, 2018 Company Industry JurisdictionThis SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company limited by shares with company registration number 00 949417 and registered in England and Wales (“Shareholder”), acting as agent for and on behalf of Invesco UK Strategic Income Fund (“Fund”).